Prince, M. J. et al. World Alzheimer Report 2015 — the global impact of dementia: an analysis of prevalence, incidence, cost and trends. Alzheimers Dis. Int. https://www.alzint.org/u/WorldAlzheimerReport2015.pdf (2021).

GBD 2019 Dementia Forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet Public Health 7, e105–e125 (2022).

Article  Google Scholar 

McKhann, G. et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34, 939–944 (1984).

Article  CAS  PubMed  Google Scholar 

Jack, C. R. Jr et al. NIA-AA research framework: toward a biological definition of Alzheimer’s disease. Alzheimers Dement. 14, 535–562 (2018).

Article  PubMed  Google Scholar 

Rabinovici, G. D. et al. Association of amyloid positron emission tomography with subsequent change in clinical management among Medicare beneficiaries with mild cognitive impairment or dementia. JAMA 321, 1286–1294 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Cummings, J. et al. Alzheimer’s disease drug development pipeline: 2022. Alzheimers Dement. 8, e12295 (2022).

Article  Google Scholar 

Liu, J. L., Hlavka, J. P., Hillestad, R. & Mattke, S. Assessing the Preparedness of the U.S. Health Care System Infrastructure for an Alzheimer’s Treatment (RAND Corporation, 2017).

Mattke, S. & Hanson, M. Expected wait times for access to a disease-modifying Alzheimer’s treatment in the United States. Alzheimers Dement. 18, 1071–1074 (2022).

Article  CAS  PubMed  Google Scholar 

Sims, J. R. et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial. JAMA 330, 512–527 (2023).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lam, J., Hlávka, J. & Mattke, S. The potential emergence of disease-modifying treatments for Alzheimer disease: the role of primary care in managing the patient journey. J. Am. Board Fam. Med. 32, 931–940 (2019).

Article  PubMed  Google Scholar 

Ritchie, C. W. et al. The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer’s disease. Alzheimers Res. Ther. 9, 85 (2017).

Article  PubMed  PubMed Central  Google Scholar 

Paczynski, M. M. & Day, G. S. Alzheimer disease biomarkers in clinical practice: a blood-based diagnostic revolution. J. Prim. Care Community Health 13, 21501319221141178 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Sideman, A. B. et al. Primary care pracitioner perspectives on the role of primary care in dementia diagnosis and care. JAMA Netw. Open 6, e2336030 (2023).

Article  PubMed  PubMed Central  Google Scholar 

Angioni, D. et al. Can we use blood biomarkers as entry criteria and for monitoring drug treatment effects in clinical trials? A report from the EU/US CTAD Task Force. J. Prev. Alzheimers Dis. 10, 418–425 (2023).

CAS  PubMed  Google Scholar 

Ovod, V. et al. Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers Dement. 13, 841–849 (2017).

Article  PubMed  Google Scholar 

Schindler, S. E. et al. High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis. Neurology 93, e1647–e1659 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Thijssen, E. H. et al. Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration. Nat. Med. 26, 387–397 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Palmqvist, S. et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324, 772–781 (2020).

Article  CAS  PubMed  Google Scholar 

Mielke, M. M. et al. Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement. 14, 989–997 (2018).

Article  PubMed  Google Scholar 

Janelidze, S. et al. Plasma p-tau181 in Alzheimer’s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer’s dementia. Nat. Med. 26, 379–386 (2020).

Article  CAS  PubMed  Google Scholar 

Mielke, M. M. et al. Performance of plasma phosphorylated tau 181 and 217 in the community. Nat. Med. 28, 1398–1405 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Janelidze, S. et al. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s disease. Brain 146, 1592–1601 (2023).

Article  PubMed  Google Scholar 

Barthelemy, N. R. et al. Highly accurate blood test for Alzheimer’s disease is similar or superior to clinical cerebrospinal fluid tests. Nat. Med. 30, 1085–1095 (2024).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoffman, P. N. et al. Neurofilament gene expression: a major determinant of axonal caliber. Proc. Natl Acad. Sci. USA 84, 3472–3476 (1987).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ashton, N. J. et al. A multicentre validation study of the diagnostic value of plasma neurofilament light. Nat. Commun. 12, 3400 (2021).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H. & Blennow, K. Association between longitudinal plasma neurofilament light and neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 76, 791–799 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Lista, S. et al. A critical appraisal of blood-based biomarkers for Alzheimer’s disease. Ageing Res. Rev. 96, 102290 (2024).

Article  CAS  PubMed  Google Scholar 

Kodosaki, E., Zetterberg, H. & Heslegrave, A. Validating blood tests as a possible routine diagnostic assay of Alzheimer’s disease. Expert Rev. Mol. Diagn. 23, 1153–1165 (2023).

Article  CAS  PubMed  Google Scholar 

Brand, A. L. et al. The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review. Alzheimers Res. Ther. 14, 195 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Plassman, B. L. et al. Incidence of dementia and cognitive impairment, not dementia in the United States. Ann. Neurol. 70, 418–426 (2011).

Article  PubMed  PubMed Central  Google Scholar 

Schubert, C. C. et al. Comorbidity profile of dementia patients in primary care: are they sicker? J. Am. Geriatr. Soc. 54, 104–109 (2006).

Article  PubMed  Google Scholar 

Sanderson, M. et al. Co-morbidity associated with dementia. Am. J. Alzheimers Dis. Other Demen. 17, 73–78 (2002).

Article  PubMed  PubMed Central  Google Scholar 

Poblador-Plou, B. et al. Comorbidity of dementia: a cross-sectional study of primary care older patients. BMC Psychiatry 14, 84 (2014).

Article  PubMed  PubMed Central